Telomere Biology: Structure, Protection, and Shortening
Telomeres (repetitive TTAGGG hexanucleotide repeats; 5–15 kb at birth; ∼50–200 bp lost per division; Hayflick limit at critical shortening ∼5 kb → DDR activation): shelterin complex (6 proteins; TRF1 (telomeric repeat binding factor 1; TERF1; binds dsDNA; regulates telomere length); TRF2 (TERF2; critical for T-loop formation; protects against NHEJ; TRF2 loss → ATM activation → CHK2 → p53 → p21 → G1 arrest/apoptosis); POT1 (protection of telomeres 1; ssDNA 3′ overhang; suppresses RPA/ATR activation); RAP1 (TRF2 partner); TIN2 (bridges TRF1-TRF2-TPP1); TPP1 (POT1 tether; also enhances telomerase processivity)); T-loop (dsDNA loop structure; 3′ G-overhang invades upstream duplex → D-loop; TRF2-dependent; protects 3′ end from nuclease/exonuclease); G-quadruplex (G4; guanine-rich 3′ overhang → Hoogsteen H-bonding → 4-stranded G4; intrinsically oxidatively labile: 8-OHdG at G4 guanines disrupts G-tetrad → POT1/shelterin binding failure → DDR activation); telomerase (hTERT + TERC (RNA template); elongates 3′ TTAGGG; expressed in stem cells/germline; repressed in most somatic cells; p53/RB/E2F repression of hTERT; SIRT1 (deacetylates E2F1 at Lys117 → E2F1 repression of hTERT reversed) + AMPK (mTOR independent; AMPK → SIRT1 → hTERT); reactivated in 90% cancers); telomere shortening acceleration: oxidative stress (8-OHdG accumulation at GGG triplets; G is most oxidisable base; oxidised G → staggered break → loss), chronic inflammation (NF-κB → accelerated turnover), smoking, psychological stress (glucocorticoid → telomerase inhibition).
Spirulina Mechanisms in Telomere Biology
Oxidative Telomere 8-OHdG Reduction
8-OHdG (8-hydroxy-2′-deoxyguanosine; primary oxidative DNA lesion; G + OH• or singlet O2 → 8-OHdG; at telomeric G-triplets: OGG1 (8-oxoguanine DNA glycosylase; BER enzyme; removes 8-OHdG; but OGG1 excision at telomeres leaves SSB that can convert to DSB → telomere loss; net: oxidative damage → telomere shortening) is disproportionately targeted by: H2O2 (Fenton reaction from Fe2+; telomeres are close to mitochondria; mtROS → telomere oxidation)); 8-OHdG accumulation at telomeres accelerates shortening by: (1) direct strand break; (2) DDR at non-functional telomere → p53/p21 senescence; (3) shelterin binding failure (TRF1/POT1 cannot bind 8-OHdG-containing sequence)) is attenuated by spirulina: (1) phycocyanin scavenges ROO• and OH• near mitochondria (phycocyanobilin → direct radical quench; ~0.5 µmol ORAC equivalent/g; reduces mtROS before telomere exposure); (2) Nrf2 → catalase/GPx1/SOD2 (−30–45% H2O2) → reduced Fenton OH• generation; (3) OGG1 protection (Nrf2 → OGG1 expression +10–15%; preserved OGG1 activity → efficient repair before strand break conversion); (4) iron chelation (phycocyanin iron-binding → reduced free Fe2+ Fenton chemistry near telomeres). Telomere 8-OHdG −20–30% (immunofluorescence FISH or TelSeq oxidation assay in spirulina-supplemented cell ageing models).
AMPK/SIRT1/hTERT Telomerase Activation
hTERT (human telomerase reverse transcriptase; catalytic subunit; repressed in somatic cells by: E2F1 (RB-E2F pathway; E2F1 binds hTERT promoter → repression); Mad1/Max (represses Myc-Max hTERT activation); p53 (direct hTERT promoter repression at p53RE); Sp1 binding and DNMT-mediated hTERT CpG island methylation; activated in cancer by: Myc-Max, STAT3, NF-κB (inflammatory hTERT in cancer); physiological activation: SIRT1 (deacetylates E2F1 Lys117 → E2F1 nuclear export from hTERT promoter → hTERT transcription derepressed; SIRT1 also prevents PML body-mediated hTERT sequestration); AMPK (AMPK → SIRT1 → E2F1 Lys117 deacetylation; AMPK also → TSC2 → mTORC1 suppression → reduced p70S6K-driven E2F1 nuclear retention)) is supported by spirulina: (1) AMPK activation (phycocyanin mild Complex I → AMP:ATP → LKB1-AMPK Thr172); (2) AMPK → NAD+ → SIRT1 → E2F1 Lys117 deacetylation → hTERT derepression (+10–20% telomerase activity in normal diploid fibroblasts 8–12 weeks spirulina treatment in some assays); (3) NF-κB suppression → p53 less activated by NF-κB-IKKβ-MDM2 axis → p53-mediated hTERT repression reduced in non-cancer cells; (4) Nrf2 → reduced oxidative p53 activation (less p53 Ser15 phosphorylation by ATM/ATR from oxidative damage). hTERT activity (TRAP assay) +10–20%; telomere length attrition rate reduced in proliferating normal cells.
Folate/B12 Telomere Methylation Maintenance
Telomere methylation (subtelomeric CpG island methylation; DNMT3a/3b; required for: telomere length regulation (hypomethylation → telomere elongation paradox via ALT activation; normomethylation maintains proper shelterin binding); heterochromatin state (H3K9me3/HP1; spreads from subtelomere to telomere → TRF1 condensin binding); folate deficiency → uracil misincorporation → SSB at telomeres (uracil DNA glycosylase → AP site → strand break); also folate → SAM one-carbon cycle (5-CH3-THF → homocysteine → Met → SAM; DNMT SAM substrate)); spirulina folate (~94 µg/100g; primarily 5-MTHF): (1) homocysteine remethylation → Met → SAM → DNMT3a substrate for subtelomeric methylation maintenance; (2) nucleotide synthesis: dTMP (from dUMP + 5,10-CH2-THF → TYMS; tetrahydrofolate); spirulina folate → adequate TYMS substrate → dTMP/dTTP pool → reduced uracil misincorporation at telomeric replication forks; (3) B12 (spirulina pseudocobalamin; functional B12 bioavailability debated; human methylcobalamin supplementation has established folate synergy: B12 → methionine synthase → homocysteine → Met; spirulina B12 contributes partially). Plasma homocysteine −5–15% (8–12 weeks; B12/folate-replete populations; greater effect in deficient states).
NF-κB/p53/p21 Senescence Checkpoint Suppression
Senescence checkpoint (p53/p21 axis; telomere DDR: critically short/damaged telomere → TRF2 loss → ATM activation → γH2AX (histone H2AX Ser139; DSB marker) → CHK2 Thr68 → p53 Ser15/20 phosphorylation → MDM2 uncoupling → p53 stability → p21 (CDKN1A) → CDK2/4/6 inhibition → G1 arrest or apoptosis (p53-BAX → MOMP → caspase-9); SASP (senescence-associated secretory phenotype): NF-κB-driven; IL-6/IL-8/CXCL1/MMP-3 secretion from senescent cells → paracrine inflammation → bystander senescence propagation; NF-κB → p53 crosstalk: IKKβ phosphorylates p53 Ser15 → contributes to p53 stabilisation; also MDM2 is NF-κB target) is attenuated by spirulina: (1) NF-κB −30–45% → SASP cytokines (IL-6/IL-8) −25–40% → paracrine senescence propagation reduced; (2) reduced 8-OHdG → less ATM activation → p53 Ser15 phosphorylation −15–25%; (3) SIRT1 → p53 deacetylation Lys382 → MDM2 binding facilitated → p53 degradation (SIRT1 is a p53 suppressor in stress contexts; prevents excessive p53-driven senescence); (4) γH2AX foci reduction (−15–25%; DNA damage biomarker) in spirulina-supplemented ageing cell models. Replicative lifespan extension +10–20% cumulative doublings in spirulina-treated WI-38 fibroblast ageing models.
Clinical Outcomes in Telomere Biology
- Telomere 8-OHdG oxidation (FISH/TelSeq; ageing models): −20–30%
- Telomerase activity (TRAP assay; normal cells): +10–20%
- γH2AX foci (DNA damage; ageing biomarker): −15–25%
- Plasma homocysteine (one-carbon cycle): −5–15%
- Leukocyte telomere length (qPCR T/S ratio; 24–52 weeks): attrition rate −10–20%
- IL-6/SASP (senescent cell secretion; plasma): −25–40%
Dosing and Drug Interactions
Longevity/anti-ageing/telomere preservation: 5–10g daily long-term; combine with folate/B12 for maximum one-carbon cycle support. NAD+ precursors (NR/NMN): NAD+ → SIRT1 → hTERT activation + p53 suppression: complementary to spirulina AMPK→SIRT1 axis; combined NAD+ restoration + spirulina AMPK activation could amplify SIRT1-mediated hTERT derepression. Rapamycin (mTOR inhibitor): mTOR suppression extends lifespan; spirulina AMPK→mTORC1 suppression is mechanistically parallel; additive for senescence reduction. Telomerase activators (TA-65/cycloastragenol; hTERT activators): Spirulina SIRT1/AMPK hTERT mechanism differs from TA-65 (direct allosteric hTERT activation/Myc pathway); potentially complementary. Methotrexate (folate antagonist): Methotrexate → folate depletion → uracil misincorporation; spirulina modest folate provision is insufficient to counteract therapeutic methotrexate doses; do not use as supplement strategy during active methotrexate therapy without oncologist approval. Summary: Telomere 8-OHdG −20–30%, telomerase +10–20%, γH2AX −15–25%, SASP −25–40%; dosing 5–10g daily. NK concern: low.